A new study looked at what methods were used to detect recurrences of human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma to see if surveillance guidelines recommended by the National Comprehensive Cancer Center were effective.
While many patients with follicular lymphoma did well with this new regimen, the majority of those who did have disease progression had transformed disease.
Among 598 trials published between 2003 and 2018, only 107 had a female corresponding author, though women made up anywhere from 27% to 39% of academic oncologists during this time period.
Patients with follicular lymphoma who were minimal residual disease-positive after undergoing involved field radiation therapy were given rituximab to see how it affected progression-free survival.
Older adults with multiple myeloma are not receiving the recommended care which includes bone-modifying drugs, antiviral prophylaxis, and the influenza vaccine.
New data push back against previous thinking that an individual's risk of progression from MGUS to multiple myeloma was constant.
Researchers from the Mayo Clinic in Rochester, Minn. examined the disease histology and outcomes of patients with diffuse large B-cell lymphoma and a concurrent lymphoma.
A combination of ibrutinib, lenalidomide, and rituximab was tested on patients with relapsed or refractory diffuse large B-cell lymphoma, particularly those with non-GCB subtype.
The United States Preventive Services Task Force issued a statement reaffirming its 2004 recommendation against screening for pancreatic cancer in asymptomatic adults.
Examining the Frequency of Late Anorectal Disease in Childhood Cancer Survivors After Pelvic Radiation
Researchers examined the rate and risk of late-onset anorectal disease among childhood cancer survivors.